ReviewJournal of endocrinological investigation2012
Recent advances in the biology of germ cell tumors: implications for the diagnosis and treatment.
Review in Journal of endocrinological investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Analysis of microsatellite instability (MSI) in pediatric gonadal and extra-gonadal germ cell tumors.Intractable & rare diseases research · 2023Article
- miRNAs and Biomarkers in Testicular Germ Cell Tumors: An Update.International journal of molecular sciences · 2021Review
- An update on microRNAs as potential novel therapeutic targets in testicular germ cell tumors.Intractable & rare diseases research · 2020Article
- Testicular Choriocarcinoma Metastasizing to the Small Bowel Causing Intussusception: Case Report.Journal of gastrointestinal cancer · 2019Article
- Extragonadal germ cell tumors: Not just a matter of location. A review about clinical, molecular and pathological features.Cancer medicine · 2019Review
- An up-date on novel molecular targets in testicular germ cell tumors subtypes.Intractable & rare diseases research · 2019Article
- c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells.International journal of molecular sciences · 2019Article
- c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors.Oncotarget · 2018Article
- Testicular cancer from diagnosis to epigenetic factors.Oncotarget · 2017Review
- An up-date on epigenetic and molecular markers in testicular germ cell tumors.Intractable & rare diseases research · 2017Article
- TDRG1 regulates chemosensitivity of seminoma TCam-2 cells to cisplatin via PI3K/Akt/mTOR signaling pathway and mitochondria-mediated apoptotic pathway.Cancer biology & therapy · 2016Article
- New perspective on molecular markers as promising therapeutic targets in germ cell tumors.Intractable & rare diseases research · 2016Article
- MicroRNAs and Recent Insights into Pediatric Ovarian Cancers.Frontiers in oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testicular germ cell tumors (TGCT), are the most frequent solid malignant tumors in men 20-40 yr of age, and the most frequent cause of death from solid tumors in this age group. TGCT can be subdivided into seminoma and nonseminoma germ cell tumors (NSGCT), including embryonal cell carcinoma, choriocarcinoma, yolk sac tumor, and teratoma. Seminomas and NSGCT do not only present distinctive clinical features, but they also show significant differences as far as therapy and prognosis are concerned. Many novel markers have given further advantages to discriminate between histological subgroups. In addition, therapeutic approaches for the treatment of TGCT have been proposed: humanized antibodies against receptors/surface molecules on cancer cells, inhibitors of serine-threonine, and tyrosine kinases, and others. The review will focus on the recent advances in the research of molecular alterations identified in TGCT and on novel targeted anti-neoplastic strategies that might help to treat chemotherapy-resistant TGCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.